Heart and Vessels

, Volume 34, Issue 12, pp 1917–1924 | Cite as

Clinical features of potential after-effects of percutaneous coronary intervention in the treatment of silent myocardial ischemia

  • Shinichiro Doi
  • Makoto SuzukiEmail author
  • Takehiro Funamizu
  • Itaru Takamisawa
  • Tetsuya Tobaru
  • Hiroyuki Daida
  • Mitsuaki Isobe
Original Article


Clinical predictors for later adverse cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) for silent myocardial ischemia remain undetermined. We investigated clinical features leading to later adverse cardiovascular events in patients who underwent PCI for silent myocardial ischemia. Of a total of 294 consecutive patients with a diagnosis of silent myocardial ischemia who successfully underwent contemporary PCI in our institute between January 2013 and December 2014, an initial event of any of all-cause death, hospitalized heart failure, acute coronary syndromes, and target vessel revascularization were identified as later adverse cardiovascular events and evaluated an association of them with baseline clinical characteristics. Silent myocardial ischemia was defined by an assessment of either electrocardiogram, myocardial perfusion imaging, coronary angiogram, or coronary fractional flow reserve. During a median follow-up of 565 days (interquartile range 361–816), later adverse cardiovascular events were identified in 38 patients (13%) consisting of 6 deaths, 5 hospitalized heart failures, 2 acute coronary syndromes, and 25 target vessel revascularizations. A presence of chronic kidney disease and/or insulin-treated diabetes mellitus, but not other clinical features, was strongly associated with later adverse cardiovascular events (hazard ratio 8.22; 95% confidential interval 2.95–29.25, P < 0.0001). Those events were increased in accordance with advanced stages of chronic kidney disease (P = 0.0003). A presence of chronic kidney disease and/or insulin-treated diabetes mellitus may lead the potential after-effects of PCI in the treatment of silent myocardial ischemia.


Silent myocardial ischemia Percutaneous coronary intervention After-effects Insulin Diabetes mellitus Chronic kidney disease 



We are sincerely grateful to Toshiaki Masuda for his profound contributions in managing the data in the present study, and are appreciative of all of the staff of Sakakibara Heart Team.

Compliance with ethical standards

Conflict of interest

This research received no grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors have no conflicts of interest to disclose.


  1. 1.
    Deedwania PC, Carbajal EV (1990) Prevalence and patterns of silent myocardial ischemia during daily life in stable angina patients receiving conventional antianginal drug therapy. Am J Cardiol 65:1090–1096CrossRefGoogle Scholar
  2. 2.
    Yeung AC, Barry J, Orav J, Bonassin E, Raby KE, Selwyn AP (1991) Effects of asymptomatic ischemia on long-term prognosis in chronic stable coronary disease. Circulation 83:1598–1604CrossRefGoogle Scholar
  3. 3.
    Abrams J (2005) Clinical practice. Chronic stable angina. N Engl J Med 352:2524–2533CrossRefGoogle Scholar
  4. 4.
    Conti CR, Bavry AA, Petersen JW (2012) Silent ischemia: clinical relevance. J Am Coll Cardiol 59:435–441CrossRefGoogle Scholar
  5. 5.
    Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503–1516CrossRefGoogle Scholar
  6. 6.
    Piccolo R, Giustino G, Mehran R, Windecker S (2015) Stable coronary artery disease: revascularization and invasive strategies. Lancet 386:702–713CrossRefGoogle Scholar
  7. 7.
    Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr (2002) ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 106:1883–1892CrossRefGoogle Scholar
  8. 8.
    Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105:539–542CrossRefGoogle Scholar
  9. 9.
    Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360:213–224CrossRefGoogle Scholar
  10. 10.
    De Bruyne B, Pijls NH, Barbato E, Bartunek J, Bech JW, Wijns W, Heyndrickx GR (2003) Intracoronary and intravenous adenosine 5-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation 107:1877–1883CrossRefGoogle Scholar
  11. 11.
    Suzuki M, Seike F, Miyoshi A, Shimizu H, Takagi Y, Sato S, Honda K (2013) Critical role of systemic inflammation in patients with ST-segment elevation myocardial infarction complicated with renal dysfunction. Int J Cardiol 168:3062–3064CrossRefGoogle Scholar
  12. 12.
    Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, den Heijer P, Vrakking MM, Wang K, Mahoney EM, Audi S, Leadley K, Dawkins KD, Kappetein AP (2011) Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med 364:1016–1026CrossRefGoogle Scholar
  13. 13.
    Suzuki M, Tomoike H, Sumiyoshi T, Nagatomo Y, Hosoda T, Nagayama M, Ishikawa Y, Sawa T, Iimuro S, Yoshikawa T, Hosoda S (2017) Incidence of cancers in patients with atherosclerotic cardiovascular diseases. Int J Cardiol Heart Vasc 17:11–16PubMedPubMedCentralGoogle Scholar
  14. 14.
    Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 60:e44–e164CrossRefGoogle Scholar
  15. 15.
    Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483CrossRefGoogle Scholar
  16. 16.
    Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382:339–352CrossRefGoogle Scholar
  17. 17.
    Hakeem A, Bhatti S, Dillie KS, Cook JR, Samad Z, Roth-Cline MD, Chang SM (2008) Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death. Circulation 118:2540–2549CrossRefGoogle Scholar
  18. 18.
    Abdel-Latif A, Mukherjee D, Mesgarzadeh P, Ziada KM (2010) Drug-eluting stents in patients with end-stage renal disease: meta-analysis and systematic review of the literature. Catheter Cardiovasc Interv 76:942–948CrossRefGoogle Scholar
  19. 19.
    Lee JM, Kang J, Lee E, Hwang D, Rhee TM, Park J, Kim HL, Lee SE, Han JK, Yang HM, Park KW, Na SH, Kang HJ, Koo BK, Kim HS (2016) Chronic kidney disease in the second-generation drug-eluting stent era: pooled analysis of the Korean multicenter drug-eluting stent registry. JACC Cardiovasc Interv 9:2097–2109CrossRefGoogle Scholar
  20. 20.
    Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222CrossRefGoogle Scholar
  21. 21.
    Margolis JR, Kannel WS, Feinleib M, Dawber TR, McNamara PM (1973) Clinical features of unrecognized myocardial infarction-silent and symptomatic. Eighteen year follow-up: the Framingham study. Am J Cardiol 32:1–7CrossRefGoogle Scholar
  22. 22.
    Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A (2006) Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 47:65–71CrossRefGoogle Scholar
  23. 23.
    Quiñones MJ, Hernandez-Pampaloni M, Schelbert H, Bulnes-Enriquez I, Jimenez X, Hernandez G, De La Rosa R, Chon Y, Yang H, Nicholas SB, Modilevsky T, Yu K, Van Herle K, Castellani LW, Elashoff R, Hsueh WA (2004) Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 140:700–708CrossRefGoogle Scholar
  24. 24.
    Shechter M, Merz CN, Paul-Labrador MJ, Kaul S (2000) Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 35:300–307CrossRefGoogle Scholar
  25. 25.
    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefGoogle Scholar
  26. 26.
    Pi SH, Rhee TM, Lee JM, Hwang D, Park J, Park TK, Yang JH, Song YB, Choi JH, Hahn JY, Kim BJ, Kim BS, Gwon HC, Choi SH (2018) Outcomes in patients with diabetes mellitus according to insulin treatment after percutaneous coronary intervention in the second-generation drug-eluting stent era. Am J Cardiol 121:1505–1511CrossRefGoogle Scholar
  27. 27.
    Goh SY, Cooper ME (2008) Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93:1143–1152CrossRefGoogle Scholar
  28. 28.
    Multiple Risk Factor Intervention Trial Research Group (1985) Exercise electrocardiogram and coronary heart disease mortality in the multiple risk factor intervention trial. Am J Cardiol 55:16–24CrossRefGoogle Scholar
  29. 29.
    Gottlieb SO, Gottlieb SH, Achuff SC, Baumgardner R, Mellits ED, Weisfeldt ML, Gerstenblith G (1988) Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients. JAMA 259:1030–1035CrossRefGoogle Scholar
  30. 30.
    Ekelund LG, Suchindran CM, McMahon RP, Heiss G, Leon AS, Romhilt DW, Rubenstein CL, Probstfield JL, Ruwitch JF (1989) Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the lipid research clinics coronary primary prevention trial. J Am Coll Cardiol 14:556–563CrossRefGoogle Scholar
  31. 31.
    Gehi AK, Ali S, Na B, Schiller NB, Whooley MA (2008) Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study. Arch Intern Med 168:1423–1428CrossRefGoogle Scholar
  32. 32.
    Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, Sopko G, Pratt C, Deanfield J, Conti CR (1997) Asymptomatic cardiac ischemia pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 95:2037–2043CrossRefGoogle Scholar
  33. 33.
    Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, Dubach P, Resink TJ, Pfisterer M (2007) Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 297:1985–1991CrossRefGoogle Scholar
  34. 34.
    Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD (2012) Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol 60:960–968CrossRefGoogle Scholar
  35. 35.
    Choi KH, Lee JM, Park I, Kim J, Rhee TM, Hwang D, Park J, Park TK, Yang JH, Song YB, Hahn JY, Jeong DS, Cho YH, Kim WS, Sung K, Jang MJ, Sung JD, Choi JH, Choi SH, Koo BK, Lee YT, Kim EK, Chang SA, Park SJ, Choi JO, Lee SC, Park SW, Cho YS, Choi JY, Gwon HC, Oh JK (2018) Comparison of long-term clinical outcomes between revascularization versus medical treatment in patients with silent myocardial ischemia. Int J Cardiol S0167–5273:32829–32838Google Scholar
  36. 36.
    Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE (2015) Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med 373:1937–1946CrossRefGoogle Scholar
  37. 37.
    Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, Keeble T, Mielewczik M, Kaprielian R, Malik IS, Nijjer SS, Petraco R, Cook C, Ahmad Y, Howard J, Baker C, Sharp A, Gerber R, Talwar S, Assomull R, Mayet J, Wensel R, Collier D, Shun-Shin M, Thom SA, Davies JE, Francis DP (2018) Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 391:31–40CrossRefGoogle Scholar
  38. 38.
    Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRefGoogle Scholar
  39. 39.
    De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Limacher A, Nüesch E, Jüni P (2014) Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 371:1208–1217CrossRefGoogle Scholar
  40. 40.
    Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of CardiologySakakibara Heart InstituteFuchuJapan
  2. 2.Department of Cardiovascular MedicineJuntendo University Graduate School of MedicineTokyoJapan
  3. 3.Department of CardiologyKawasaki Saiwai HospitalKawasakiJapan

Personalised recommendations